Brought to you by 
Series A brings in $6mm for Ocugen
16 Dec 2016
Executive Summary
Ocugen Inc. (therapies for ocular diseases) raised $6mm in a Series A financing led by a group of ex-pharma executives as well as EB5 Life Sciences (contributed $1mm).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A brings in $6mm for Ocugen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice